Ganoderal A
(Synonyms: 灵芝醛A) 目录号 : GC36111
Ganoderal A 是灵芝中的一种氧化甾醇，能作为胆固醇合成抑制剂。
Cas No.:104700-98-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Ganoderal A, an oxygenated sterol from G. lucidum, is a cholesterol synthesis inhibitor[1].
[1]. Hajjaj H, et al. Effect of 26-oxygenosterols from Ganoderma lucidum and their activity as cholesterol synthesis inhibitors. Appl Environ Microbiol. 2005 Jul;71(7):3653-8.
| Cas No. | 104700-98-3 | SDF | |
| 别名 | 灵芝醛A | ||
| Canonical SMILES | CC1(C)C(CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@H](C)CC/C=C(C)/C=O)CC[C@](C)4C3=CC[C@@]12[H])=O | ||
| 分子式 | C30H44O2 | 分子量 | 436.67 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2901 mL | 11.4503 mL | 22.9006 mL |
| 5 mM | 0.458 mL | 2.2901 mL | 4.5801 mL |
| 10 mM | 0.229 mL | 1.145 mL | 2.2901 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Ganoderal A effectively induces osteogenic differentiation of human amniotic mesenchymal stem cells via cross-talk between Wnt/β-catenin and BMP/SMAD signaling pathways
Biomed Pharmacother 2020 Mar;123:109807.PMID:31896066DOI:10.1016/j.biopha.2019.109807.
Osteogenic inducers play central roles in effective stem cell-based treatment of bone defects/losses. However, the current routine osteogenic inducer is a cocktail comprising three components that must be improved due to low induction efficiency and side effects. Therefore, there is an urgent need to develop safer and more effective osteoinducers. Herein, we demonstrated the osteogenic effect of Ganoderal A (GD-A), a tetracyclic triterpenoid compound from Ganoderma lucidum. GD-A showed no cytotoxicity toward human amniotic mesenchymal stem cells (hAMSCs) at doses of 0.001-10 μM; furthermore, 0.01 μM GD-A significantly induced the generation of osteoblast-specific markers, such as alkaline phosphatase, and calcium deposition in hAMSCs. At molecular levels, GD-A promoted the expression of multiple osteoblast differentiation markers, such as RUNX2, OSX, OPN, ALP, OCN, and COL1α1. Both Wnt/β-catenin and BMP/SMAD signaling were shown as active during hAMSC osteodifferentiation. Furthermore, specific blocking of both signals by KYA1797K and SB431542 significantly inhibited alkaline phosphatase secretion and RUNX2 and ALP expression when used alone or in combination. Meanwhile, both signals were also blocked. These findings suggest that GD-A induces hAMSC differentiation into osteoblasts through signaling cross-talk between Wnt/β-catenin and BMP/SMAD. Taken together, GD-A is a safe, effective, and novel osteoinducer and might be used for stem cell-based therapy for bone defects/losses.
Cytotoxic lanostane-type triterpenes from the fruiting bodies of Ganoderma lucidum
Nat Prod Res 2022 Nov 16;1-6.PMID:36382774DOI:10.1080/14786419.2022.2146107.
A new lanostane-type triterpene, namely 3-oxo-5α-lanosta-7,9(11)-dien-24-oic acid methyl ester (2), and three known compounds including Ganoderal A (1), ganoderiol B (3) and ganodermenonol (4) were isolated from the fruiting bodies of Ganoderma lucidum by silica gel column chromatography and Sephadex LH-20 column chromatography. Their structures were determined by extensive NMR data and mass spectral analysis. The in vitro cytotoxic activity of the isolated compounds against SK-Hep-1, HepG2, Hela and Hela/VCR cancer cell lines was assessed by using MTT assay. The IC50 values of compound 1 were 43.09 ± 2.86, 42.31 ± 1.78 and 46.51 ± 1.95 μM in SK-Hep-1, HepG2 and Hela cells, respectively, after 48 h. The IC50 values of compound 4 were 44.70 ± 2.32 and 41.33 ± 2.15 μM in Hela and Hela/VCR cells, respectively, after 48 h.
Effect of 26-oxygenosterols from Ganoderma lucidum and their activity as cholesterol synthesis inhibitors
Appl Environ Microbiol 2005 Jul;71(7):3653-8.PMID:16000773DOI:10.1128/AEM.71.7.3653-3658.2005.
Ganoderma lucidum is a medicinal fungus belonging to the Polyporaceae family which has long been known in Japan as Reishi and has been used extensively in traditional Chinese medicine. We report the isolation and identification of the 26-oxygenosterols ganoderol A, ganoderol B, Ganoderal A, and ganoderic acid Y and their biological effects on cholesterol synthesis in a human hepatic cell line in vitro. We also investigated the site of inhibition in the cholesterol synthesis pathway. We found that these oxygenated sterols from G. lucidum inhibited cholesterol biosynthesis via conversion of acetate or mevalonate as a precursor of cholesterol. By incorporation of 24,25-dihydro-[24,25-3H2]lanosterol and [3-3H]lathosterol in the presence of ganoderol A, we determined that the point of inhibition of cholesterol synthesis is between lanosterol and lathosterol. These results demonstrate that the lanosterol 14alpha-demethylase, which converts 24,25-dihydrolanosterol to cholesterol, can be inhibited by the 26-oxygenosterols from G. lucidum. These 26-oxygenosterols could lead to novel therapeutic agents that lower blood cholesterol.
Antiinflammatory triterpenoids and steroids from Ganoderma lucidum and G. tsugae
Phytochemistry 2008 Jan;69(1):234-9.PMID:17655889DOI:10.1016/j.phytochem.2007.06.008.
The antiinflammatory properties of triterpenoids and steroids from both Ganoderma lucidum and Ganoderma tsugae were studied. Twelve compounds, including ergosta-7,22-dien-3beta-ol (1), ergosta-7,22-dien-3beta-yl palmitate (2), ergosta-7,22-dien-3-one (3), ergosta-7,22-dien-2beta,3alpha,9alpha-triol (4), 5alpha,8alpha-epidioxyergosta-6,22-dien-3beta-ol (5), Ganoderal A (6), ganoderal B (7), ganoderic aldehyde A (8), tsugaric acid A (9), 3-oxo-5alpha-lanosta-8,24-dien-21-oic acid (10), 3alpha-acetoxy-5alpha-lanosta-8,24-dien-21-oic acid ester beta-d-glucoside (11), and tsugaric acid B (12), were assessed in vitro by determining their inhibitory effects on the chemical mediators released from mast cells, neutrophils, and macrophages. Compound 10 showed a significant inhibitory effect on the release of beta-glucuronidase from rat neutrophils stimulated with formyl-Met-Leu-Phe (fMLP)/cytochalasin B (CB) whereas compound 9 significantly inhibited superoxide anion formation in fMLP/CB-stimulated rat neutrophils. Compound 10 also exhibited a potent inhibitory effect on NO production in lipopolysaccharide (LPS)/interferon-gamma (IFN-gamma)-stimulated N9 microglial cells. Moreover, compound 9 was also able to protect human keratinocytes against damage induced by ultraviolet B (UV B) light, which indicated 9 could protect keratinocytes from photodamage.
Quality evaluation of Ganoderma through simultaneous determination of nine triterpenes and sterols using pressurized liquid extraction and high performance liquid chromatography
J Sep Sci 2006 Nov;29(17):2609-15.PMID:17313101DOI:10.1002/jssc.200600178.
A method combining HPLC and pressurized liquid extraction was developed for simultaneous quantification of nine components, including eight triterpenes (ganoderic acid A, ganoderic acid Y, ganoderic acid DM, ganoderol A, ganoderol B, Ganoderal A, methyl ganoderate D and ganoderate G) and a sterol (ergosterol), in Ganoderma. The determination was achieved by using a Zorbax ODS C18 analytical column (4.6 x 250 mm id, 5 microm) and gradient elution with diode-array detection. All calibration curves showed good linearity (r2 > 0.9997) within the test ranges. The developed method showed good repeatability for the quantification of the nine investigated components in Ganoderma with intra- and inter-day variations of less than 2.4% and 4.1%, respectively. The validated method was successfully applied to quantify the nine components in two species of Ganoderma, i.e. G. lucidum and G. sinense, used as Lingzhi in China. Furthermore, hierarchical clustering analysis based on the nine components in HPLC profiles from the tested 11 samples showed that chemical characteristics were significantly different between G. lucidum and G. sinense, which suggested that clinical investigation should be performed so as to ensure the safety and efficacy of medication.